Zynerba Pharmaceuticals, Inc. (NasdaqGM: ZYNE)
Health Care · Pharmaceuticals · US
$—
— today · — 1Y
Zynerba Pharmaceuticals, Inc. (NasdaqGM: ZYNE) operates in the Pharmaceuticals industry within the Health Care sector.
Tweenvest scores Zynerba Pharmaceuticals, Inc. across four factors: quality 28/100. Its strongest factor is quality.
ZYNE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.80
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $—
- 52-week low
- $—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 25
- Next earnings
- —
About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals, Inc. is a specialized pharmaceutical firm currently in the clinical development phase. Its primary objective is to create and advance medicinal transdermal cannabinoid treatments specifically for uncommon and scarcely encountered neuropsychiatric conditions. A key product in its pipeline is Zygel, a pharmaceutical-grade cannabidiol expertly crafted into a gel with enhanced skin penetration for topical application. Originally established as AllTranz, Inc., the company adopted its current name, Zynerba Pharmaceuticals, Inc., in August 2014. Founded in 2007, Zynerba Pharmaceuticals maintains its headquarters in Devon, Pennsylvania.
- ISIN
- US98986X1090
- Founded
- 2007
- Listed since
- Aug 5, 2015
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,245.48 | -0.79% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $273.59 | +1.24% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $151.07 | -0.97% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.01 | -0.21% |
Figures last refreshed Aug 18, 2026.